Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, and industrial markets. The company operates through three reportable segments: Human Nutrition and Health, which provides choline nutrients, mineral amino acid chelates, vitamin K2, and methylsulfonylmethane (MSM) for human nutrition, food, and beverage applications; Animal Nutrition and Health, which supplies choline chloride, microencapsulated products, and chelated minerals for ruminant, monogastric, and companion animal feed; and Specialty Products, which repackages and distributes performance gases such as ethylene oxide, propylene oxide, and ammonia, and sells Metalosate chelated minerals for agricultural use. Balchem serves customers globally through its own sales force, independent distributors, and sales agents, with manufacturing locations in the United States and Europe. Founded in 1967, the company holds over 130 patents and 400 registered trademarks.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Specialty Chemicals Homepage balchem.com
Sector Basic Materials IR page balchem.com/investors
Tags
choline, amino acid chelates, vitamin k2, methylsulfonylmethane, microencapsulation, animal feed additives, ethylene oxide, propylene oxide, ammonia, chelated minerals, plant nutrition, sterilization gases, Metalosate
Press page balchem.com/investors/press-releases

Metrics

Valuation  
Market cap $ 5.25B
Market cap (USD) $ 5.25B
P/E 31.07
PEG 2.27
P/BV 3.96
P/S 4.73
P/OCF 23.46
P/FCF 30.33
Dividend yield 0.58%
Turnover / mcap —
Returns  
ROE 12.9%
ROI 10.9%
ROIC 11.5%
Profit margin 14.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 13.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 13.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 52
Quality score 15.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.037B 953.684M 922.439M 942.358M 799.023M 703.644M 643.705M 643.679M 594.79M 553.204M 552.492M 541.383M 337.173M 310.393M 291.867M 255.071M 219.438M 232.05M 176.201M — — 67.406M 61.875M 60.197M 46.142M 33.198M
Net profit 154.845M 128.475M 108.543M 105.367M 96.104M 84.623M 79.671M 78.573M 90.071M 55.972M 59.722M 52.826M 44.874M 40.005M 38.765M 33.277M 26.785M 19.05M 16.118M 12.278M 10.954M 8.026M 5.638M 7.416M 5.11M 3.729M
Free cash flow 173.067M 146.338M 145.869M 89.45M 124.372M 118.414M 98.671M 99.527M 83.092M 84.578M 62.526M 72.151M 47.505M 39.898M 38.29M 31.473M 44.643M 17.817M 10.768M 14.091M 11.929M 10.93M 8.883M 94K 1.272M 5.072M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 153.36 163 148.75 122.11 168.6 115.22 101.63 78.35 80.6 83.92 60.8 66.64 58.7 36.45 40.57 33.83 33.33 25.63 14.67 — — — — — — —
Price performance 12m -0.06 0.1 0.22 -0.28 0.46 0.13 0.3 -0.03 -0.04 0.38 -0.09 0.14 0.61 -0.1 0.2 0.01 0.3 0.75 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 83.3M 91.2M 99.5M 93.4M 98.2M 117M 132M 125M 120M 144M
↳ YoY growth +37.6% +9.6% +9.1% -6.1% +5.1% +19.5% +12.1% -4.8% -4.5% +20.0%
↳ 5y CAGR +19.3% +16.8% +20.4% +5.4% +10.2% +7.1% +7.6% +4.7% +5.1% +7.9%
Borrowings, current (USD) 35M 35M 0.00 2.48M — — — — — —
Borrowings, non-current (USD) 226M 184M 156M — — — — — — —
Lease liabilities (USD) — — 0.00 4.83M 8.42M 9.48M 20M 20.8M 18M 16.7M
Cash and deposits (USD) 38.6M 40.4M 54.3M 65.7M 84.6M 103M 66.6M 64.4M 49.5M 74.6M
Intangible assets (USD) 147M 128M 106M 144M 122M 94.7M 213M 191M 165M 133M
Right-of-use assets (USD) — — 0.00 7.34M 5.84M 6.93M 17.1M 17.8M 15.3M 14.7M
Net debt (borrowings + leases - cash) (USD) 223M 179M 102M -58.4M — — — — — —
Cash flow detail
Operating cash flow (USD) 108M 111M 119M 124M 150M 161M 139M 184M 182M 217M
Purchases of property, plant and equipment (USD) -23M -27.5M -19.2M -25.8M -32.1M -36.1M -49.1M — — —
Purchases of intangible assets (USD) -963,000 -591,000 -553,000 — — — — — — —
Change in receivables (cash effect) (USD) -15.7M -3.91M -7.77M 11.6M -3.6M -20.7M -3.62M 6.97M 5.58M -20.9M
Change in inventories (cash effect) (USD) 4.75M -319,000 -6.02M -11.4M 13.9M -21M -7.8M 10.5M -22.8M 3.64M
Change in payables (cash effect) (USD) 17.8M 1.51M 5.99M 1.13M -992,000 47.1M -15.5M 3.55M 9.07M 11.3M
Dividends paid (cash effect) (USD) -10.7M -12.1M -13.4M -15.1M -16.7M -18.7M -20.7M -22.9M -25.6M -28.3M
Share buybacks (cash effect) (USD) -1.59M -1.91M -1.39M -21.3M -13.5M -35.2M -35.4M -4.47M -5.68M -108M
Interest paid (cash effect) (USD) -6.67M -7.02M -6.94M -5.67M -4.67M -4.55M -11.9M -25.9M -17.7M -10.6M
Income taxes paid (cash effect) (USD) -30.7M -25.8M -20.6M -21.8M -22.6M -25.4M -33M -35.7M -42.6M -37.7M
Share-based compensation (USD) 7.02M 6.26M 6.41M 7.6M 8.3M 10.8M 13.2M 16.1M 16.7M 18.1M
Operating cash flow before change in receivables (USD) 123M 115M 126M 113M 154M 181M 142M 177M 176M 237M
Free cash flow (OCF - PPE - intangibles) (USD) 83.6M 82.5M 99M 98.7M 118M 124M 89.5M — — —
Income detail
Research and development expense (USD) 7.33M 9.31M 11.6M 11.4M 10.3M 13.5M 12.2M 15M 16.8M 18.5M
↳ 5y CAGR +20.4% +22.1% +26.2% +18.8% +11.5% +13.0% +5.6% +5.4% +8.1% +12.4%
Total comprehensive income (USD) -1.74M 5.15M -1.96M -1.96M 9.74M -9.17M -2.16M 124M 96M 220M
Comprehensive income to owners (USD) 54.2M 95.3M 76.6M 77.7M 94.4M 86.9M 103M 124M 96M 220M
Provision for credit losses (USD) 258,000 69,000 43,000 1.78M 140,000 180,000 401,000 37,000 299,000 -97,000
Credit cost ratio (credit losses / average receivables) (%) 0.4% 0.1% 0.0% 1.8% 0.1% 0.2% 0.3% 0.0% 0.2% 0.1%
Reported Feb 28, 2017 Mar 1, 2018 May 3, 2019 Feb 21, 2020 Feb 19, 2021 Feb 24, 2022 Feb 24, 2023 Feb 16, 2024 Feb 21, 2025 Feb 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

View Press Release

Balchem announced they will participate in Baird’s Global Industrial Conference on November 11, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference.

Related Press Releases.

View all

[October 23, 2026
\

Balchem Reports Third Quarter 2026 Financial Results](https://balchem.com/news/balchem-reports-third-quarter-2026-financial-results/)

[October 9, 2026
\

Balchem Announces Conference Call for Third Quarter 2026 Financial Results](https://balchem.com/news/balchem-announces-conference-call-for-third-quarter-2026-financial-results-2/)

[September 9, 2026
\

Balchem Corporation to Participate in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026](https://balchem.com/news/balchem-corporation-to-participate-in-the-9th-annual-wells-fargo-consumer-conference-on-september-23-2026/)

Also of Interest -

Balchem home

Address

Balchem Headquarters
5 Paragon Drive
Montvale, NJ 07645

[(845) 326-5600](tel:(845) 326-5600)

Navigation

© 2026 Balchem Corp., All rights reserved.
Balchem and other marks on this website are trademarks of Balchem Corporation or its subsidiaries.

Notice

You are now leaving the Balchem Corporation website and linking to a non-affiliated third Party site.

I Understand

Balchem Corporation Reports Third Quarter 2026 Financial Results

Montvale, NJ, October 23, 2026 - Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal third quarter ended September 30, 2026. For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA(a) of $80.3 million, and free cash flow(a) of $57.9 million.

Ted Harris, Chairman, President and CEO of Balchem, said, “Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA.”

Third Quarter 2026 Financial Highlights:

•Net sales were $290.7 million, an increase of 8.6% from the prior year quarter.

•GAAP net earnings were $46.7 million, an increase of 16.0% from the prior year quarter.

•Adjusted EBITDA was $80.3 million, an increase of 12.4% from the prior year quarter.

•GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter and adjusted earnings per share(a) were $1.57 compared to $1.35 in the prior year quarter.

Balchem Reports Third Quarter 2026 Financial Results Bull 3 Bear 0 Results

Ted Harris, Chairman, President and CEO of Balchem said, “With strong results through the first nine months of the year and a healthy balance sheet, Balchem is well positioned to continue executing our strategic growth initiatives, and we remain excited about the future of our company.”

Balchem Corporation reported financial results for its 2026 fiscal third quarter ended September 30, 2026. For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA(a) of $80.3 million, and free cash flow(a) of $57.9 million.

Ted Harris, Chairman, President and CEO of Balchem, said, “Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA.”

Third Quarter 2026 Financial Highlights:

  • Net sales were $290.7 million, an increase of 6% from the prior year quarter.

  • GAAP net earnings were $46.7 million, an increase of 0% from the prior year quarter.

  • Adjusted EBITDA was $80.3 million, an increase of 4% from the prior year quarter.

  • GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter and adjusted earnings per share(a) were $1.57 compared to $1.35 in the prior year quarter.

  • Cash flows from operations were $69.8 million, with free cash flow of $57.9 million.

  • Sales and earnings from operations growth in all three of our reporting segments.

Recent Highlights:

  • At the upcoming SupplySide Global trade show, we will showcase several of our latest Human Nutrition and Health technologies and innovations, including new science supporting VitaCholine®, K2VITAL™, Optifolin+® and OptiMSM®, as well as advances in performance nutrition and functional food and beverage applications. These innovations highlight the strength of our pipeline and our continued focus on developing differentiated, science-backed solutions that address important human health and wellness trends.

  • Balchem repurchased approximately $28 million of common stock during the third quarter and approximately $127 million over the trailing twelve months, reflecting the Company’s balanced capital allocation strategy and commitment to long-term shareholder value creation.

Quarterly Conference Call

A quarterly conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter 2026 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO, will host the call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or +1-585-542-9983 (International Toll), and referencing Meeting ID: 831870284, five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/831870284. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/831870284 for one year.

(a) See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures.

Prompts

Balchem Corporation (ticker BCPC), listed in United States.

ETFs Holding Balchem Corporation

ETF Weight in ETF Shares Market value As of
RSMC 2.34% 99,946 $ 17.139M Nov 17, 2026
ALIL 2.33% 2,831 $ 480K Nov 18, 2026
SMCO 1.73% 14,780 $ 2.534M Nov 17, 2026
HSMV 1.56% 501 $ 85.911K Nov 16, 2026
SDVD 0.87% 46,210 $ 8.008M Nov 11, 2026
FSEG 0.80% 269 $ 45.448K Jun 30, 2026
FESM 0.57% 196,606 $ 33.217M Jun 30, 2026
LITL 0.54% 182 $ 30.873K Nov 17, 2026
FSEV 0.53% 210 $ 35.48K Jun 30, 2026
MMSC 0.53% 1,559 $ 267.337K Nov 16, 2026
SCDS 0.53% 286 $ 48.514K Nov 17, 2026
PAPI 0.50% 11,923 $ 2.014M Jun 30, 2026
SIXL 0.41% 4,982 $ 858.648K Nov 12, 2026
SEIS 0.27% 9,231 $ 1.56M Jun 30, 2026
RESM 0.22% 47 $ 7,940.65 Jun 30, 2026
JMEE 0.18% 30,250 $ 5.131M Nov 17, 2026
PSC 0.17% 23,828 $ 4.026M Jun 30, 2026
DFAS 0.13% 242,909 $ 41.865M Nov 12, 2026
SMDX 0.11% 812 $ 139.242K Nov 17, 2026
AVSC 0.08% 14,441 $ 2.476M Nov 16, 2026
FEAC 0.05% 69 $ 11.658K Jun 30, 2026
MSSM 0.02% 1,004 $ 176.594K Aug 31, 2026
FELV 0.02% 4,383 $ 740.508K Jun 30, 2026
DFAC 0.02% 107,427 $ 18.515M Nov 12, 2026
DFSU 0.02% 2,727 $ 469.998K Nov 12, 2026
DCOR 0.01% 36,843 $ 6.35M Nov 12, 2026
DXUV 0.01% 3,730 $ 642.866K Nov 12, 2026
DFAU 0.01% 7,048 $ 1.215M Nov 12, 2026
DFUV 0.01% 7,903 $ 1.362M Nov 12, 2026
DFUS 0.01% 9,500 $ 1.637M Nov 12, 2026
EBI 0.00% 104 $ 18.293K Aug 31, 2026
AVUS 0.00% 3,184 $ 545.992K Nov 16, 2026
AVSU 0.00% 100 $ 17.148K Nov 16, 2026